EP0952842A2 — A method of treating cancer
Assigned to Merck and Co Inc · Expires 1999-11-03 · 27y expired
What this patent protects
The present invention relates to a method of treating cancer which comprises administering to a mammalian patient an effective amount of a combination of geranylgeranyl-protein transferase-type I inhibitor and a farnesyl protein transferase inhibitor. The invention further relate…
USPTO Abstract
The present invention relates to a method of treating cancer which comprises administering to a mammalian patient an effective amount of a combination of geranylgeranyl-protein transferase-type I inhibitor and a farnesyl protein transferase inhibitor. The invention further relates to a method of treating cancer which comprises administering to a mammalian patient an effective amount of a combination of a selective geranylgeranyl-protein transferase-type I inhibitor and a selective farnesyl protein transferase inhibitor. The figure shows the autoradiograph of the immunoprecipates from assay set No. 1 of the in vivo prenylation inhibition by a combination by a selective of FPTase inhibitor and a selective geranylgeranyl-protein transferase-type I inhibitor.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.